Adial Pharmaceuticals Operating Expenses Growth & History (ADIL)
Adial Pharmaceuticals's operating expenses was $7.8M for fiscal 2025.
View full Adial Pharmaceuticals company overviewAdial Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.8M | −$484,995 | −5.85% |
| 2024 | 2024-12-31 | $8.3M | $1.4M | +20.27% |
| 2023 | 2023-12-31 | $6.9M | −$4.0M | −36.57% |
| 2022 | 2022-12-31 | $10.9M | −$8.4M | −43.70% |
| 2021 | 2021-12-31 | $19.3M | $8.4M | +76.51% |
| 2020 | 2020-12-31 | $10.9M | $2.7M | +32.54% |
| 2019 | 2019-12-31 | $8.2M | $1.3M | +18.00% |
| 2018 | 2018-12-31 | $7.0M | $6.0M | +602.03% |
| 2017 | 2017-12-31 | $995,286 | — | — |
Adial Pharmaceuticals quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $52.0M | $50.1M | +2664.35% |
| Q1 2026 | 2026-03-31 | $2.0M | −$265,812 | −11.72% |
| Q4 2025 | 2025-12-31 | $1.9M | −$54,640 | −2.82% |
| Q3 2025 | 2025-09-30 | $1.8M | −$447,396 | −20.23% |
| Q2 2025 | 2025-06-30 | $1.9M | −$405,230 | −17.72% |
| Q1 2025 | 2025-03-31 | $2.3M | $422,271 | +22.89% |
| Q4 2024 | 2024-12-31 | $1.9M | $808,843 | +71.46% |
| Q3 2024 | 2024-09-30 | $2.2M | $853,538 | +62.86% |
| Q2 2024 | 2024-06-30 | $2.3M | $809,835 | +54.82% |
| Q1 2024 | 2024-03-31 | $1.8M | −$1.1M | −36.83% |
| Q4 2023 | 2023-12-31 | $1.1M | −$870,200 | −43.46% |
| Q3 2023 | 2023-09-30 | $1.4M | −$1.2M | −46.84% |
| Q2 2023 | 2023-06-30 | $1.5M | −$1.8M | −54.45% |
| Q1 2023 | 2023-03-31 | $2.9M | −$138,226 | −4.52% |
| Q4 2022 | 2022-12-31 | $2.0M | −$4.0M | −66.53% |
| Q3 2022 | 2022-09-30 | $2.6M | −$1.5M | −37.13% |
| Q2 2022 | 2022-06-30 | $3.2M | −$1.2M | −26.34% |
| Q1 2022 | 2022-03-31 | $3.1M | −$1.8M | −36.80% |
| Q4 2021 | 2021-12-31 | $6.0M | $2.5M | +72.34% |
| Q3 2021 | 2021-09-30 | $4.1M | $725,177 | +21.72% |
| Q2 2021 | 2021-06-30 | $4.4M | $2.6M | +142.12% |
| Q1 2021 | 2021-03-31 | $4.8M | $2.5M | +110.43% |
| Q4 2020 | 2020-12-31 | $3.5M | $1.4M | +65.99% |
| Q3 2020 | 2020-09-30 | $3.3M | $1.6M | +91.23% |
| Q2 2020 | 2020-06-30 | $1.8M | −$340,218 | −15.76% |
| Q1 2020 | 2020-03-31 | $2.3M | $50,979 | +2.27% |
| Q4 2019 | 2019-12-31 | $2.1M | $1.0M | +91.80% |
| Q3 2019 | 2019-09-30 | $1.7M | −$2.1M | −54.25% |
| Q2 2019 | 2019-06-30 | $2.2M | $417,543 | +23.98% |
| Q1 2019 | 2019-03-31 | $2.2M | $1.9M | +562.50% |
| Q4 2018 | 2018-12-31 | $1.1M | — | — |
| Q3 2018 | 2018-09-30 | $3.8M | $3.6M | +1354.22% |
| Q2 2018 | 2018-06-30 | $1.7M | $1.5M | +621.15% |
| Q1 2018 | 2018-03-31 | $339,513 | — | — |
| Q3 2017 | 2017-09-30 | $262,416 | — | — |
| Q2 2017 | 2017-06-30 | $241,485 | — | — |
Adial Pharmaceuticals operating expenses trends
Over the last five fiscal years, Adial Pharmaceuticals's operating expenses decreased from $10.9M to $7.8M, a change of −$3.1M. The latest reported quarter, Q2 2026, shows $52.0M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adial Pharmaceuticals source filings ↗